Tyrosine Kinase Inhibitor as a new Therapy for Ischemic Stroke and other Neurologic Diseases: is there any Hope for a Better Outcome?

Author(s): Iwona Gagalo, Izabela Rusiecka, Ivan Kocic

Journal Name: Current Neuropharmacology

Volume 13 , Issue 6 , 2015

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


The relevance of tyrosine kinase inhibitors (TKIs) in the treatment of malignancies has been already defined. Aberrant activation of tyrosine kinase signaling pathways has been causally linked not only to cancers but also to other non-oncological diseases. This review concentrates on the novel plausible usage of this group of drugs in neurological disorders, such as ischemic brain stroke, subarachnoid hemorrhage, Alzheimer’s disease, multiple sclerosis. The drugs considered here are representatives of both receptor and non-receptor TKIs. Among them imatinib and masitinib have the broadest spectrum of therapeutic usage. Both drugs are effective in ischemic brain stroke and multiple sclerosis, but only imatinib produces a therapeutic effect in subarachnoid hemorrhage. Masitinib and dasatinib reduce the symptoms of Alzheimer’s disease. In the case of multiple sclerosis several TKIs are useful, including apart from imatinib and masitinib, also sunitinib, sorafenib, lestaurtinib. Furthermore, the possible molecular targets for the drugs are described in connection with the underlying pathophysiological mechanisms in the diseases in question. The most frequent target for the TKIs is PDGFR which plays a pivotal role particularly in ischemic brain stroke and subarachnoid hemorrhage. The collected data indicates that TKIs are very promising candidates for new therapeutic interventions in neurological diseases.

Keywords: Alzheimer’s disease, multiple sclerosis, ischemic brain stroke, subarachnoid hemorrhage, tyrosine kinases, tyrosine kinase inhibitors.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Page: [836 - 844]
Pages: 9
DOI: 10.2174/1570159X13666150518235504
Price: $65

Article Metrics

PDF: 37